Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
Clinical trial NCT05834738 · COMPLETED
Trial details
- NCT number
- NCT05834738
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-20
- Primary completion
- 2025-06-30
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.